WallStreetZenWallStreetZen

NASDAQ: ADIL
Adial Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ADIL stock forecasts and price targets.

Forecast return on equity

Is ADIL forecast to generate an efficient return?

Company
-54.41%
Industry
85.8%
Market
169.74%
ADIL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ADIL forecast to generate an efficient return on assets?

Company
-38.69%
Industry
29.42%
ADIL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADIL earnings per share forecast

What is ADIL's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$6.24
Avg 2 year Forecast
-$2.64
Avg 3 year Forecast
-$1.70

ADIL revenue forecast

What is ADIL's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$22.2M

ADIL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADIL$2.30N/AN/A
BRTX$0.19N/AN/A
DRMA$1.24N/AN/A
PULM$1.37N/AN/A
PPBT$2.70$30.00+1,011.11%Buy
View Top Biotech Stocks

Adial Pharmaceuticals Stock Forecast FAQ

What is ADIL's earnings growth forecast for 2026-2028?

(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Adial Pharmaceuticals's earnings in 2026 is -$7,770,762.On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$13,370,407, with the lowest ADIL earnings forecast at -$15,419,495, and the highest ADIL earnings forecast at -$11,006,422. On average, 3 Wall Street analysts forecast ADIL's earnings for 2027 to be -$5,663,018, with the lowest ADIL earnings forecast at -$5,440,939, and the highest ADIL earnings forecast at -$5,829,577.

In 2028, ADIL is forecast to generate -$3,651,444 in earnings, with the lowest earnings forecast at -$3,508,250 and the highest earnings forecast at -$3,758,839.

If you're new to stock investing, here's how to buy Adial Pharmaceuticals stock.

What is ADIL's revenue growth forecast for 2026-2028?

(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Adial Pharmaceuticals's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ADIL's revenue for 2026 to be $0, with the lowest ADIL revenue forecast at $0, and the highest ADIL revenue forecast at $0. On average, 3 Wall Street analysts forecast ADIL's revenue for 2027 to be $0, with the lowest ADIL revenue forecast at $0, and the highest ADIL revenue forecast at $0.

In 2028, ADIL is forecast to generate $47,622,684 in revenue, with the lowest revenue forecast at $45,753,447 and the highest revenue forecast at $49,022,469.

What is ADIL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ADIL) forecast ROA is -38.69%, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is ADIL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ADIL) Adial Pharmaceuticals's current Earnings Per Share (EPS) is -$8.71. On average, analysts forecast that ADIL's EPS will be -$6.24 for 2026, with the lowest EPS forecast at -$7.19, and the highest EPS forecast at -$5.13. On average, analysts forecast that ADIL's EPS will be -$2.64 for 2027, with the lowest EPS forecast at -$2.54, and the highest EPS forecast at -$2.72. In 2028, ADIL's EPS is forecast to hit -$1.70 (min: -$1.64, max: -$1.75).

What is ADIL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ADIL) forecast ROE is -54.41%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.